Drug Database
BE

beclometasone dipropionate (Qnasl / Qnaze)

✓ Approved

Teva Pharmaceutical Industries Ltd. · NR3C1 · Small Molecule

What is beclometasone dipropionate?

beclometasone dipropionate is a small molecule developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via inhaled.

Drug Profile

Brand NamesQnasl, Qnaze
CompanyTeva Pharmaceutical Industries Ltd.
Drug ClassSmall Molecule
Molecular TargetNR3C1
RouteInhaled
StatusApproved
Sources: ClinicalTrials.gov, Teva Pharmaceutical Industries Ltd.

Mechanism of Action

Molecular Targets

beclometasone dipropionate acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

beclometasone dipropionate is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved
Immune system disordersSeasonal allergy✓ Approved

Related Research Articles

PubMedItalian journal of dermatology and venereology2026-08-24

Topical treatment of psoriasis with calcipotriol/betamethasone dipropionate cream in real-life clinical practice: expert opinion.

Gisondi Paolo P, Burlando Martina M, Esposito Maria M, Megna Matteo M et al.

The fixed-dose combination of calcipotriol and betamethasone dipropionate (Cal/BDP) is an established topical psoriasis treatment. The cream formulation of Cal/BDP has been found effective and well-tolerated for the treatment of mild-to-moderate disease, with high levels of patient satisfaction. The aim of this consensus document is to guide optimal real-life use of Cal/BDP cream in patients with psoriasis. Eight hospital-based dermatologists, with long-standing experience in psoriasis treatment, developed a consensus document on three topics (therapeutic protocols and schedules; high-impact areas; and treatment adherence) regarding the use of Cal/BDP cream in clinical practice. A modified Delphi process was used to achieve consensus among panel members. Statements with treatment recommendations, based on the experts' opinions and experience, as well as an analysis of relevant published data, were elaborated on and discussed during two meetings occurring two months apart. Full agreement among panel members was obtained after two online Delphi rounds. As seen in clinical trials, Cal/BDP cream monotherapy has proved beneficial in the treatment of mild to moderate plaque psoriasis. However, it can also be used as an adjunct to systemic/biologic drug treatment or as long-term maintenance therapy. Cal/BDP cream also plays an important role in the treatment of psoriasis on high-impact sites (including the scalp, peripheral facial areas, skin folds and palmoplantar areas) with treatment schedules varying according to disease severity and area involved. Due to its vehicle, treatment with Cal/BDP cream is associated with high levels of treatment convenience and patient acceptability, positively impacting adherence. Cal/BDP cream can be used safely and effectively for the treatment of psoriasis in a range of clinical presentations. Its favorable cosmetic characteristics contribute to treatment success by enhancing patient adherence. Studies on the long-term use of Cal/BDP cream as a maintenance therapy are needed.

PMID 42634951
Read full article →
PubMedOrthopedic research and reviews2026-08-12

Effect Of Intraarticular Triamcinolone Hexacetonide versus Betamethasone on Intraocular Pressure: A Prospective Randomized Study.

Yağar Hilal H, Biçer Kadir Eren KE, Yıldırım Biçer Gamze G

Corticosteroids may cause glaucoma by increasing intraocular pressure (IOP) due to their systemic side effects. Few studies have investigated the effect of intraarticular corticosteroids (IACS) on IOP. This study aimed to evaluate the effects of IACS preparations (betamethasone and triamcinolone hexacetonide) on IOP. In this single-center randomized study, patients receiving IACS were randomized into two groups: Group 1 received betamethasone (Diprospan®, betamethasone dipropionate 6.43 mg + betamethasone sodium phosphate 2.63 mg, equivalent to 7.0 mg betamethasone) and Group 2 received triamcinolone hexacetonide (Artropan®,20 mg triamcinolone hexacetonide). IOP was measured before injection and at 1 week after injection. The change in IOP (ΔIOP) was calculated using the following formula: IOP (after injection) - IOP (before injection). A total of 80 patients and 160 eyes were included in the study, with 40 patients in each group. No significant change was found in ΔIOP in Group 1 (p > 0.05). A statistically significant increase in ΔIOP was observed in both eyes and in the left eye in Group 2; (both eyes: p = 0.002; left eye: p = 0.012; right eye:p = 0.060). ΔIOP was significantly higher in Group 2 than in Group 1 (p = 0.043). Triamcinolone hexacetonide may increase IOP after IACS more than betamethasone; caution is warranted in patients with risk factors for glaucoma. The trial was registered at ClinicalTrials.gov retrospectively (No: NCT07242846, Date: 17.11.2025).

PMID 42583198
Read full article →
PubMedTierarztliche Praxis. Ausgabe K, Kleintiere/Heimtiere2026-08-12

Clinicopathological abnormalities, treatment, and outcome in in a 45-day-old puppy with acute Babesia canis infection.

Schäfer Ingo I, Stüwe Sophia S, Fürst Kathrin K, Strube Christina C et al.

The knowledge regarding Babesia canis infections in puppies is limited to 3 dogs aged 43-46 days. A 45-day-old, male intact German Shepherd dog was presented due to lethargy, inappetence, and gait disorders. An acute Babesia canis infection was diagnosed by PCR. Marked thrombocytopenia, anemia, and hyperbilirubinemia were noted. A subcutaneous injection of imidocarb dipropionate (ID, 2.0 mg/kg bodyweight) was applied. The puppy's general condition significantly improved, but vomitus was noted. A negative PCR and mild hematological abnormalities were seen 14 days later. A second subcutaneous injection of ID (4.2 mg/kg bodyweight) was applied. Babesia canis infections should be considered in puppies with fever, marked thrombocytopenia, and marked anemia in the immunological gap. Next to vectorial transmission, transplacental Babesia canis infections are reported but considered unlikely in the presented puppy. The puppy responded well to a lower-ranged dose of ID, but side effects were noted (vomiting). In adult dogs, treatment of acute Babesia canis infections using ID dosed 6.6 mg/kg bodyweight is recommended. No safety regulations are published by the manufacturer regarding the use of ID in puppies, but vomitus is reported as a potential side effect after the use in adult dogs. A second ID injection (4.2 mg/kg bodyweight) was applied to avoid a potential disease relapse. The case report highlights the significance of the immunological gap in puppies with Babesia canis infections and the need for ectoparasite prophylaxis in puppies, if vector contact is possible.

PMID 42586170
Read full article →
PubMedDermatology and therapy2026-08-10

Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study.

Bewley Anthony A, Pinter Andreas A, López Estebaranz José Luis JL, Galván Jordi J et al.

Scalp psoriasis is often associated with poor adherence to topical therapy. A novel formulation of calcipotriol and betamethasone dipropionate based on polyaphron dispersion (CAL/BDP PAD-cream) showed improved outcomes and satisfaction in the PRO-SCALP study, particularly in patients with high adherence. We evaluated how adherence to CAL/BDP PAD-cream influences patients- and clinicians-reported outcomes and treatment preferences in mild-to-moderate scalp psoriasis under real-life conditions in Europe. PRO-SCALP patients reported their adherence level using a visual analogue scale (VAS). Outcomes were compared between low- and high-adherence subgroups. Among 252 patients, 59.9% reported high adherence (VAS 80-100). Older patients and those with moderate disease reported high adherence (both p < 0.05). High-adherent patients reported higher scores in the Treatment Satisfaction Questionnaire for Medication Version 9, for Convenience of use (p = 0.0019) and Global Satisfaction (p = 0.0166) domains, and in the Psychosocial Effects of Scalp Psoriasis Questionnaire (p = 0.0004) at week 8. Both adherence subgroups showed significant reductions in the scalp Worst Itch Numeric Rating Scale (WI-NRS), scalp-modified Psoriasis Area and Severity Index (S-mPASI), and Scalpdex scores (all p < 0.0001 vs. baseline), although high-adherent patients achieved greater improvements in WI-NRS (p < 0.0001), S-mPASI (p = 0.0153), and the Scalpdex Symptoms domain (p = 0.001) than low-adherent. Each 10% increase in adherence corresponded to a 0.10- and 0.35-point reduction in S-mPASI and WI-NRS (both p < 0.05) at week 8. Scalp-Physician Global Assessment success rates were comparable in low- vs. high-adherence subgroups (65.0% vs. 70.5%; p = 0.3633). Sleep quality improved significantly in both subgroups (p < 0.0001). High adherence was associated with higher Patient Preference Questionnaire scores (p = 0.0012), better Cream Usability Scalp Psoriasis Questionnaire ratings (p = 0.0455) and greater product consumption (p < 0.0001), despite similar once-a-day usage. High adherence to CAL/BDP PAD-cream was associated with greater effectiveness, satisfaction, preference, and QoL. While patients with low adherence still benefited, maximizing adherence is key for optimal real-world outcomes in scalp psoriasis. ClinicalTrials.gov identifier NCT05811234.

PMID 42573965
Read full article →
PubMedArchives of biochemistry and biophysics2026-08-04

GPR97-Gα12-mTORC1 signaling drives myotube hypertrophy: identification of 5-hydroxy-7-methoxyflavone as a pathway activator.

Fujita Shuhei S, Kimura Ayano A, Maekawa Daisuke D, Kubota Mai M et al.

Elucidating novel signaling pathways that drive myotube hypertrophy may provide new insights into the mechanisms regulating skeletal muscle growth. We previously reported that 5-hydroxy-7-methoxyflavone (HMF) induces hypertrophy of murine C2C12 myotubes; however, the underlying molecular mechanism remains unclear. Here, loss- and gain-of-function analyses revealed that GPR97 positively regulates myotube size. Furthermore, knockdown and rescue experiments demonstrated that GPR97 is required for HMF-induced myotube hypertrophy. HMF activated mTORC1 signaling in myotubes, and intramuscular administration of HMF also activated mTORC1 signaling in mouse skeletal muscle in vivo. Gpr97 knockdown abolished HMF-induced mTORC1 signaling and protein synthesis. Furthermore, depletion of Gna12 and expression of dominant-negative Gα12 abolished HMF-induced myotube hypertrophy. Gna12 depletion also suppressed HMF-induced mTORC1 signaling and protein synthesis. Beclomethasone dipropionate, a reported GPR97 ligand, suppressed HMF-induced hypertrophy and mTORC1 signaling, while further enhancing HMF-induced serum response factor (SRF)-dependent transcription. Although dominant-negative RhoA inhibited HMF-induced SRF-dependent transcriptional activity, it did not affect myotube hypertrophy. These findings indicate that GPR97-Gα12-mTORC1 signaling promotes hypertrophy independent of the Gα12-RhoA-SRF pathway. GPR97 was predominantly expressed on the myotube surface as a C-terminal fragment generated by N-terminal fragment (NTF) cleavage, and HMF reduced its surface expression. HMF induced hypertrophy in myotubes expressing an NTF cleavage-resistant GPR97 mutant, but not in those expressing an NTF-deleted mutant. These results indicate that NTF cleavage is dispensable and suggest that NTF contributes to GPR97-mediated hypertrophic signaling. These findings identify a novel GPR97-Gα12-mTORC1 signaling axis that mediates HMF-induced myotube hypertrophy.

PMID 42546894
Read full article →
PubMedEuropean journal of internal medicine2026-08-02

Particle engineering, aerosol physics, and pulmonary deposition of single-inhaler triple ICS/LABA/LAMA therapies in obstructive airway diseases.

Sorino Claudio C, Virchow Johann Christian JC, Spanevello Antonio A, Buscemi Agata A et al.

Single-inhaler triple therapy (SITT) combining an inhaled corticosteroid, long-acting β2-agonist, and long-acting muscarinic antagonist (ICS/LABA/LAMA) represents the current ceiling of inhaled pharmacotherapy for moderate-to-very-severe chronic obstructive pulmonary disease and severe uncontrolled asthma. Five device platforms are currently approved: two extrafine formulations delivering beclomethasone dipropionate/formoterol/glycopyrronium (the Modulite solution pressurised metered-dose inhaler [pMDI] and the NEXThaler breath-actuated dry powder inhaler [DPI]); the co-suspension pMDI Aerosphere platform (budesonide/glycopyrrolate/formoterol); the standard-particle Ellipta DPI (fluticasone furoate/umeclidinium/vilanterol); and the low-resistance, single-dose capsule-based DPI Breezhaler (mometasone furoate/indacaterol/glycopyrronium). Despite a shared pharmacological class, these systems differ in aerosol physics, particle engineering, intrapulmonary deposition patterns, and device-patient interaction. Furthermore, some of them are authorized only for COPD or asthma. This narrative review examines the technology and in vivo deposition evidence for each SITT platform, discusses real-world performance determinants (particle size, flow dependency, technique robustness), and proposes an expert-informed framework for patient-level device selection. Methodological limitations include reliance on in silico Functional Respiratory Imaging data when in vivo scintigraphy is unavailable, and inconsistent dose denominators across studies (emitted vs. metered dose). Cross-platform comparisons are limited by heterogeneous methodologies, and no SITT platform has demonstrated universal superiority. In platform-specific studies, NEXThaler shows relatively high lung deposition (∼55% of emitted dose) though flow-dependent; Aerosphere is robust to inhalation technique variations; Modulite provides extrafine, peripheral delivery; Ellipta and Breezhaler offer once-daily convenience with moderate deposition. Rational device selection requires structured assessment of patient inspiratory capacity, disease phenotype, coordination, and adherence. Head-to-head scintigraphy and prospective imaging-outcome studies represent major evidence gaps.

PMID 42542404
Read full article →

+3749 more articles available with a free account

Sign up free to view all articles →

Ask about beclometasone dipropionate